NSE: NATCOPHARM | BSE: 524816

Mid-range Performer

Download real time

935.40 2.85 (0.31%)

37.85% Fall from 52W High

2.2M NSE+BSE Volume

NSE 03 Dec, 2025 3:31 PM (IST)

16,753.9

Market Cap

High in industry

Beta 1Year

Very High Volatility

Natco Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for NATCOPHARM, BSE:524816 Natco Pharma Ltd.

Natco Pharma Ltd.

16 Nov 2015

935.40

0.31%

Natco Pharma - 2QFY16 Result Update

Buy: Natco Pharma Ltd.

Reliance Securities

3. gSovaldi contributed Rs630mn in 2Q (Rs230mn from B2B business) with operating margins at 28-30%. We believe Sovaldi is an interesting opportunity for the Indian market and Natco's first mover advantage will give it a significant...

Natco Pharma has lost -33.90% in the last 1 Year

Natco Pharma Ltd.

13 Aug 2015

935.40

0.31%

Natco Pharma - 1QFY16 Result Update

Buy: Natco Pharma Ltd.

Reliance Securities

Natco Pharma's 1QFY16 performance has been in-line on the operating and profitability front despite a 5% miss in top-line impacted by dismal export formulations and lumpy API sales. Surge in gross margins at 67.6% (up 200bps yoy) led to steady improvement in EBITDA at 22.9% (up 290 bps yoy). Traction in base portfolio of domestic oncology and gSovaldi (Rs370mn in 1Q) were key highlights. Management has guided for sales of Rs10.5-11bn and PAT of Rs1.6bn in FY16E assuming: 1) Sovaldi ramp up in India-guided Rs1.5bn sales 2) Commencement of Venezuela tender business 3) No commercial launches in US. However, the...

Number of MF schemes decreased from 47 to 19 in Sep 2025 qtr

Natco Pharma Ltd.

19 Jun 2015

935.40

0.31%

Natco Pharma Event Update: US Court ruling in favour of Natco regarding Copaxone (Jun 19, 2015)

Buy: Natco Pharma Ltd.

Karvy

On June 18, 2015, the US Federal Circuit Court ruled in favour of Natco by invalidating Teva's process patent 5,800,808. This means Natco can launch generic Copaxone 20 mg as soon as it receives US FDA approval.

Natco Pharma Ltd. has an average target of 845.00 from 2 brokers.

Natco Pharma Ltd.

25 May 2015

935.40

0.31%

Natco Pharma Ltd: Q4 FY15 Results - Rise In API Business Margins, But Formulatio... (May 25, 2015)

Natco Pharma Ltd.

Karvy

Natco Pharma Ltd reported Rs. 2,008 Mn in Net Revenues for Q4 FY15, up by 9.2% YoY, and up by 2.7% on a QoQ basis. Net Revenues increased on the back of higher sales of Formulations which rose by 9.3% YoY and 22.7% QoQ. Also, Bulk Chemicals contributed significantly to the top line, sales of Bulk Chemicals rose by 65.1% YoY and 13.1% on a QoQ basis.

Natco Pharma Ltd. has an average target of 845.00 from 2 brokers.

Natco Pharma Ltd.

12 Mar 2015

935.40

0.31%

Natco Pharma: Key Developments (Mar 12, 2015)

Natco Pharma Ltd.

Karvy

Karvy initiated the coverage on Natco Pharma on 23rd Jan, 2015 at a price ofRs.1,362 with a price target of Rs.1,770, which has been achieved. We plan torelease an updated report shortly. Please click here to read the key developments.

Natco Pharma Ltd. is trading above all available SMAs

Natco Pharma Ltd.

13 Feb 2015

935.40

0.31%

Natco Pharma Ltd - Q3YF15 Results - First Cut (Feb 13, 2015)

Buy: Natco Pharma Ltd.

Karvy

Natco: Near term volatility; Long term triggers intact:Although financial metrics of Natco fell on a QoQ basis, they have risen on 9 months basis (9mFY15 vs 9mFY14). Net revenue fell by 11% to Rs.1955 mn QoQ, primarily because of fall in Venezuela exports. But on a 9 months basis revenue increased by 12.5%.

ICICI Securities Limited downgraded Natco Pharma Ltd. to Sell with a price target of 750.0 on 15 Nov, 2025.

Natco Pharma Ltd.

23 Jan 2015

935.40

0.31%

Natco Pharma Ltd. (Jan 23, 2015)

Buy: Natco Pharma Ltd.

Karvy

Karvy initiates coverage of Natco Pharma with a Buy Rating. Generic Copaxone is still a big opportunity despite US Supreme Court ruling. Natco to launch generic Sovaldi, another blockbuster drug for treatment of Hepatitis C, in India in 1QFY16. Tamiflu lawsuit currently ongoing, Natco is expected to prevail in the case allowing it to win 180-day exclusivity.

Natco Pharma Ltd. is trading above all available SMAs

Is Natco Pharma Ltd. worth buying?

594 Votes:

Buy 83.0%

Sell 7.41%

Hold 9.6%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf